Direct thrombin inhibitors: Pharmacology and clinical relevance

Anaesthesia

Volumn 60, Issue 6, 2005, Pages 565-574

  Kam, P C A ^a   Kaur, N ^a   Thong, C L ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTIDOTE; ANTITHROMBIN; ANTIVITAMIN K; ARGATROBAN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 9; DESULFATOHIRUDIN; ENOXAPARIN; FIBRINOGEN; FIBRINOGEN RECEPTOR; FRESH FROZEN PLASMA; HEPARIN; HIRUDIN; HIRULOG; INOGATRAN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MEIZOTHROMBIN; MELAGATRAN; PROTHROMBIN; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN; THROMBIN INHIBITOR; THROMBOCYTE FACTOR 4; THROMBOXANE A2; WARFARIN; XIMELAGATRAN;

ANTICOAGULATION; ARTERY THROMBOSIS; BLEEDING DISORDER; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CRYOPRECIPITATE; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BINDING SITE; DRUG CLASSIFICATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG POTENCY; HEART MUSCLE ISCHEMIA; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; PATHOPHYSIOLOGY; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA; THROMBOEMBOLISM; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANTICOAGULANTS; ANTITHROMBINS; AZETIDINES; BENZYLAMINES; FIBRINOLYTIC AGENTS; HIRUDINS; HUMANS; PIPECOLIC ACIDS; THROMBOSIS;

EID: 19944395865     PISSN: 00032409     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2044.2005.04192.x     Document Type: Review

References (88)

1. Furic B, Furic BC. Molecular and cellular biology of blood coagulation. New England Journal of Medicine 1992; 326: 800-6.
2. Friedman DG. The structure of thrombin. In: Colman RW, Hirsh J, Marder V, Salzman EW, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 2nd edn. Philadelphia: JB Lippincott, 1987: 71-2.
3. Lensing AWA, Prandoni P, Prins MH, Buller HR. Deep vein thrombosis. Lancet 1999; 353: 479-85.
4. Bates S, Weitz J. Emerging anticoagulant drugs. Arteriosclerosis, Thrombosis and Vascular Biology 2003; 23: 1491-500.
5. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657-71.
6. Davie EW. Biochemical and molecular aspects of the coagulation cascade. Thrombosis and Haemostasis 1995; 75: 1-6.
7. Herrmann JP, Serruys P. Thrombin and antithrombotic therapy in interventional cardiology. Texas Heart Institute Journal 1994; 21: 138-47.
8. Mann K, Butenas S, Brummel K. The dynamics of thrombin formation. Arteriosclerosis Thrombosis and Vascular Biology 2003; 23: 17-25.
9. Hirsch J. Current anticoagulant therapy - unmet clinical needs. Thrombosis Research 2003; 109: S1-8.
10. Price GC, Thompson SA, Kam PCA. Tissue factor and tissue factor pathway inhibitor. Anaesthesia 2004; 59: 483-92.
11. Weitz J. A novel approach to thrombin inhibition. Thrombosis Research 2003; 109: S17-22.
12. Despotis G, Joist JH. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: An update. Journal of Cardiothoracic and Vascular Anesthesia 1999; 13 (Suppl. 1): 18-29.
13. Weitz J, Buller H. Direct thrombin inhibitors in acute coronary syndromes: Present and Future. Circulation 2002; 105: 1004-11.
14. Weitz JL. Low molecular weight heparins. New England Journal of Medicine 1997; 337: 688-98.
15. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy: 1. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. British Medical Journal 1994; 308: 81-106.
16. Eikelboom J, White H, Yusuf S. The evolving role of direct thrombin inhibitors in acute coronary syndromes. Journal of the American College of Cardiology 2003; 41: 70S-78S.
17. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119: 64S-94S.
18. Hirsh J, Bates SM. The emerging role of low-molecular weight heparin in cardiovascular medicine. Progress in Cardiovascular Disease 2000; 42: 235-46.
19. Weitz J, Hudoba M, Massel D, Maranganore J, Hirsh J. Clot bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. Journal of Clinical Investigation 1990; 86: 385-91.
20. Warkentin TE. Thrombotic complications of anticoagulant therapy. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN, eds. Basic Principles and Clinical Practice: Hemostasis and Thrombosis. Philadelphia: Lippincott, Williams & Wilkins, 2001: 1371-82.
21. Stubbs MT, Bode W. A player of many parts: the spotlight falls on thrombin's structure. Thrombosis Research 1993; 9: 1-58.
22. Hogg PJ, Bock PE. Modulation of thrombin and heparin activities by fibrin. Thrombosis Haemostasis 1997; 77: 424-33.
23. Liaw PC, Becker DL, Stafford AR. Molecular basis for the susceptibility of fibrin-bound thrombin inactivation by heparin co-factor II in the presence of dermatan sulfate but not heparin. Journal of Biological Chemistry 2001; 276: 20959-65.
24. Weitz J, Crowther M. Direct thrombin inhibitors. Thrombosis Research 2002; 106: 275-84.
25. Salzet M. Leech thrombin inhibitors. Current Pharmaceutical Design 2002; 8: 125-33.
26. Fink E. Comparisons of hirudins. Seminars in Thrombosis and Haemostasis 1989; 15: 283-7S.
27. Mueller R, Scheidt S. History of drugs for thrombotic disease: discovery, development and directions for the future. Circulation 1994; 89: 432-49.
28. Markwardt TF. Historical perspective of the development of thrombin inhibitors. Pathophysiology of Haemostasis and Thrombosis 2002; 32 (Suppl. 3): 15-22.
29. Stone SR, Maraganore JM. Hirudin interactions with thrombin. In: Thrombin: Structure and Function. New York: Plenum Press, 1992: 219-28.
30. Lefevre G, Duval M, Gauron S, et al. Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin. Clinical Pharmacology and Therapeutics 1997; 62: 50-9.
31. Stringer KA, Lindenfeld J. Hirudins: antithrombin anticoagulants. Annals of Pharmacotherapeutics 1992; 26: 1535-40.
32. Markwardt F, Nowak G, Bucha E. Clinical pharmacology of recombinant hirudin. Haemostasis 1991; 21: 133-6.
33. O'Shea S, Ortel T, Kovalik E. Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopaenia. Seminars in Dialysis 2003; 16: 61-7.
34. Willey M, De Denus S, Spinler S. Removal of lepirudin, a recombinant hirudin, by hemodialysis, haemofiltration, or plasmapheresis. Pharmacotherapy 2002; 22: 492-9.
35. Vanholder R, Camez A, Veys N, et al. Pharmacokinetics of recombinant hirudin in haemodialyzed end-stage renal failure patients. Thrombosis and Haemostasis 1997; 77: 650-5.
36. Warkentin T, Crowther M. Reversing anticoagulants both old and new. Canadian Journal of Anaesthesia 2002; 49 (Suppl. 1): 11-25.
37. Greinacher A, Lubenow N. Recombinant hirudin in clinical practice: focus on lepirudin. Circulation 2001; 103: 1479-84.
38. Hafner G, Rupprecht HJ, Luz M, et al. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris. European Heart Journal 1996; 17: 1207-15.
39. Denus S, Spinler S. Clinical monitoring of direct thrombin inhibitors using the ecarin clotting time. Pharmacotherapy 2002; 22: 433-5.
40. Warkentin T. Heparin-induced thrombocytopaenia and the anaesthesiologist. Canadian Journal of Anaesthesia 2002; 49: s36-s49.
41. Nurmohamed MT, Berckmans RJ, Morrien-Salomons WM, et al. Monitoring anticoagulant therapy by activated partial thromboplastin time: hirudin assessment. Thrombosis and Haemostasis 1994; 72: 685-92.
42. Despotis G, Hogue C, Saleem R, et al. The relationship between hirudin and activated clotting time: implications for patients with heparin-induced thrombocytopaenia undergoing cardiac surgery. Anesthesia and Analgesia. 2001; 93: 28-32.
43. The Direct Thrombin Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patient's data. Lancet 2002; 359: 294-302.
44. Nicolaides AN. Clinical results with direct thrombin inhibitors. Pathophysiology of Haemostasis and Thrombrosis 2002; 32 (Suppl. 3): 36-8.
45. Maraganore JM, Bourdon P, Jablonski J, et al. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990; 29: 7095-101.
46. Weitz J, Hirsh J. New antithrombotic agents. Chest 1998; 114: 715-27 S.
47. Bates SM, Weitz J. Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin. American Journal of Cardiology 1998; 82: S12-8.
48. Nawarskas J, Anderson J. Bivalirudin: a new approach to anticoagulation. Heart Disease 2001; 3: 131-7.
49. Fox I, Dawson A, Loynds P, et al. Anticoagulant activity of hirulog, a direct thrombin inhibitor, in humans. Thrombosis and Haemostasis 1993; 69: 157-63.
50. Cannon C, Maraganore J, Loscalzo J, et al. Anticoagulant effects of hirulog, a novel antithrombin inhibitor, in patients with coronary artery disease. American Journal of Cardiology 1993; 71: 778-82.
51. Brittl J, Strony J, Brinker J, et al. Treatment with bivalirudin as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. New England Journal of Medicine 1995; 333: 764-9.
52. Koster A, Chew D, Gruendel M, et al. An assessment of different filter systems for extracorporeal elimination of bivalirudin: an in vitro study. Anesthesia and Analgesia 2003; 96: 1316-9.
53. Reed M, Bell D. Clinical pharmacology of bivalirudin. Pharmacotherapy 2002; 22: 105S-11S.
54. Stratmann G, DeSilva A, Tseng E, Hambleton J, et al. Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopaenia. Anesthesia and Analgesia 2004; 98: 1635-9.
55. Kathiresan S, Shinomura J, Jang IK. Argatroban. Journal of Thrombosis and Thrombolysis 2002; 13: 41-7.
56. Fitzgerald D, Murphy N. Argatroban: a synthetic thrombin inhibitor of low relative molecular mass. Coronary Artery Disease 1996; 7: 455-8.
57. Hursting MJ, Alford KL, Becker JC, et al. Novostan (brand of argatroban): a small molecule, direct thrombin inhibitor. Seminars in Thrombosis and Haemostasis 1997; 23: 503-16.
58. Swan SK, St Peter JV, Lambrecht LJ, Hursting MJ. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects. Pharmacotherapy 2000; 20: 756-70.
59. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000; 20: 318-9.
60. Kondo LM, Wittkowsky AK, Wiggins BS. Argatroban for prevention and treatment of thromboembolism in heparin-induced thrombocytopaenia. Annals of Pharmacotherapy 2001; 35: 440-51.
61. Anonymous. Argatroban. Prescribing information. Philadelphia: Smith-Kline Beecham, 2000.
62. Gustafsson D. Oral direct thrombin inhibitors in clinical development. Journal of International Medicine 2003; 254: 322-34.
63. Gustafsson D, Nystrom J-E, Carlsson S, Bredberg U, Eriksson U, et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thrombosis Research 2001; 101: 171-81.
64. de Moerloose P, Boehlen F. Two new antithrombotic agents (fondaparinux and ximelagatran) and their implications in anaesthesia. Canadian Journal of Anaesthesia 2002; 49: S5-10.
65. Eriksson UG, Bredberg U, Gislen K, et al. Pharmacokinetics and pharmacodynamic of ximelgatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. European Journal of Clinical Pharmacology 2003; 59: 35-43.
66. Hrebickova L, Nawarskas J, Anderson J. Ximelagatran: a new oral anticoagulant. Heart Disease 2003; 5: 397-408.
67. Clement B, Lopian K. Characterization of in vitro biotransformation of a new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug. Drug Metabolism and Disposition 2003; 31: 645-51.
68. Bredberg E, Andersson TB, Frison L, et al. Ximelagatran, an oral direct thrombin inhibitor, has low potential for cytochrome P450-mediated drug-drug interactions. Clinical Pharmacokinetics 2003; 42: 765-77.
69. Johanssson LC, Frison L, Logren U, et al. Influence of age on the pharmacokinetics and pharmacodynamics of ximelgatran, an oral direct thrombin inhibitor. Clinical Pharmacokinetics 2003; 42: 381-92.
70. Eriksson BI, Bergqvist D, Dahl OE, Lindbratt S, Kalebo P, et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomized trial. Lancet 2002; 360: 1441-7.
71. Kessler C. Current and future challenges of antithrombotic agents and anticoagulants: strategies for reversal of hemorrhagic complications. Seminars in Haematology 2004; 41 (Suppl. 1): 44-50.
72. ten Cate H, Bauer K, Levi M, et al. The activation of factor X and prothrombin by recombinant factor V11a in vivo is mediated by tissue factor. Journal of Clinical Investigation 1993; 92: 1207-12.
73. Hoffmann M, Monroe DM, Roberts HR. Activated factor VII activates Factors IX and X on the surface of activated platelets: Thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagulation and Fibrinolysis 1998; 9: S61-5.
74. Levi M, Bijsterveld NR, Keller T. Recombinant Factor V11a as an antidote for anticoagulant treatment. Seminars in Haematology 2004; 41 (Suppl 1): 65-9.
75. Roberts H, Monroe D, Escobar M. Current concepts of hemostasis: implications for therapy. Anaesthesiology 2004; 100: 722-30.
76. Tee BK, Chong BH. Heparin-induced thrombocytopaenia and thrombosis syndrome: in vivo cross-reactivity with danaparoid and successful treatment with r-Hirudin. British Journal of Haematology 2001; 114: 394-6.
77. Koster A, Kukucka M. Anticoagulation of patients with heparin-induced thrombocytopaenia in cardiac surgery. Current Opinion in Anaesthesiology 2004; 17: 71-4.
78. Warkentin T, Greinacher A. Heparin induced thrombocytopaenia and cardiac surgery. Annals of Thoracic Surgery 2003; 76: 638-48.
79. O'Shea S, Ortel T, Kovalik E. Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopaenia. Seminars in Dialysis 2003; 16: 61-6.
80. Matsuo T, Kario K, Chikahira Y, Nakao K, Yamada T. Treatment of heparin-induced thrombocytopaenia by use of argatroban, a synthetic thrombin inhibitor. British Journal of Haematology 1992; 82: 627-9.
81. Pernerstofer T, Hollenstein U, Hansen J, et al. Lepirudin blunts endotoxin-induced coagulation activation. Blood 2000; 95: 1729-34.
82. Rosencher N. Ximelagatran, a new oral direct thrombin inhibitor, for the prevention of venous thromboembolic events in major elective orthopaedic surgery. Efficacy, safety and anaesthetic considerations. Anaesthesia 2004; 59: 803-10.
83. Greinacher A, Volpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with the immunologic type of heparin-induced thrombocytopenia: a prospective study. Circulation 1999; 99: 73-80.
84. Greinacher A, Janssens U, Berg G, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 1999; 100: 587-93.
85. Eichler P, Friesen HJ, Lubenow N, Jaegar B, Greinacher A. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects of aPTT, and clinical relevance. Blood 2000; 96: 2372-8.
86. Warkentin TE. Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban. Thrombosis Research 2003; 110: 73-82.
87. Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Archives of International Medicine 2003; 163: 1849-56.
88. Potzsch B, Madlener K. Management of cardiopulmonary bypass anticoagulation in patients with heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia, 2nd edn. New York: Marcel Dekker Inc., 2001: 429-44.